|
|
|
|
Science Sparks @ ACTREC
|
 16 December 2024 |
Vol. No. 13 ; Issue No.660 |
|
|
Publications
|
|
1. Jog E, Jainarayanan AK, Ferlita A, Chakraborty A, Dalwai A, Yahya S, Shivashankar A, Choudhary B, Chandramouli A, Kazi M, Jain D, Khapre N, Akshaya B, Khan B, Gera P, Patil P, Thorat R, Verma N, Sehgal L, Saklani A, Kamat S, Dalal SN, Choudhary N (2024). Inhibiting de novo lipogenesis identifies a therapeutic vulnerability in therapy-resistant colorectal cancer. Redox Biology.
Book Chapter
Naorem L, Shrivastava K, Chandrani P (2025). Deep learning in personalized genomics and gene editing. In: Raza K (Ed.) Deep Learning in Genetics and Genomics. Vol II, Advanced Apllications. Academic Press. Pp. 151-170.
|
|
|
|
|
Interesting Reads
|
|
Kang HJ, Krumm BE, Tassou A, Geron M, DiBerto JF, Kapolka NJ, Gumpper RH, Sakamoto K, Dewran Kocak D, Olsen RHJ, Huang XP, Zhang S, Huang KL, Zaidi SA, Nguyen MT, Jo MJ, Katritch V, Fay JF, Scherrer G, Roth BL. Structure-guided design of a peripherally restricted chemogenetic system. Cell. 2024
|
|
|
Video of the Week
|
|
| Lung Cancer: New Frontiers in Diagnosis & Treatment to Challenge the Old Paradigm |
|
| |
|
|
| |
|
|
|
|
Do You Know?
In 2016, Atezolizumab (Tecentriq) became the first PD-L1-targeting immune checkpoint inhibitor approved by FDA.
|
|
|
|
Cancer News
|
| |
|
A “Living Medicine:” engineered E. coli shrink tumors in mice.
|
|
National Cancer Institute, 11/12/2024
|
|
In the first study, the researchers engineered E. coli to deliver small bits of tumor proteins to immune cells. Like giving a search-and-rescue dog an old T-shirt of a missing person, the bacteria show the immune cells what the tumor looks like so they can find and attack it...
|
| |
|
|
|
|
| |
|
|
|
Lipid imbalances hold the key to chronic inflammation in colon cancer.
|
|
News-Medical, 12/12/2024
|
|
The study found that colorectal cancer tissues exhibit a significant pro-inflammatory lipid profile compared to normal tissues. The quantitative lipidomics analysis identified elevated levels of AA-derived mediators, including leukotrienes and 5-hydroxyeicosatetraenoic acid (5-HETE),...
|
|
|
|
|
|
|
|
|
2024 Advanced Centre for Treatment, Research and Education in Cancer (ACTREC)
|
|
